Neoleukin Therapeutics Current Assets

The latest current assets for NLTX is $250M as of March 2026. That compares with $300M in the prior-year period — down 16.8% year over year. Investors often review this figure alongside Neoleukin Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NLTX's current assets moved from $300M to $250M — a 16.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neoleukin Therapeutics's operating scale or balance-sheet position.

A current assets figure of $250M for NLTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NLTX's current assets ($250M), review year-over-year change from $300M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Neoleukin Therapeutics's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.